-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

Benzinga·09/30/2026 18:00:57
Listen to the news
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.